{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004057","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.044715+00:00","generated_at":"2026-05-28T05:30:04.214273+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path","bullets":["Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).","DYNE-101 in DM1: 6.8 mg/kg Q8W dose showed robust splicing correction at 3 months and sustained functional improvements.","DYNE-101 safety: 855 doses administered, >72 patient-years follow-up; no related serious TEAEs.","Plans ~32-patient Registrational Expansion Cohort for DYNE-101 in mid-2025; U.S. accelerated approval submission targeted H1 2026.","DYNE-251 for DMD exon 51: FDA supports dystrophin as surrogate endpoint; data from 20 mg/kg cohort expected late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004057","json":"https://secwatch.observer/filing/0001193125-25-004057.json","markdown":"https://secwatch.observer/filing/0001193125-25-004057.md","text":"https://secwatch.observer/filing/0001193125-25-004057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/0001193125-25-004057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/d909941d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:30:04.214273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}